Description
The IA10 monoclonal antibody specifically binds to CD55, which is also known as complement decay-accelerating factor (DAF). CD55 is a glycophosphatidylinositol (GPI)-anchored, single chain membrane glycoprotein of approximately 70 kDa that belongs to the regulators of complement activation (RCA) gene family which includes CD21, CD35, and CD46. CD55 is widely expressed on hematopoietic cells including platelets and erythrocytes, as well as on many non-hematopoietic cells, such as, endothelial cells and epithelial cells. CD55 is involved in protecting cells from damage by autologous activated complement complexes. CD55 prevents the amplification steps of the complement cascade by interfering with the assembly of the C3-convertases, C4b2a and C3bBb, and the C5-convertases, C4b2a3b and C3bBb3b.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. An isotype control should be used at the same concentration as the antibody of interest.
10. CF™ is a trademark of Biotium, Inc.
11. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
Specifications

General

BrandBD OptiBuild™
Alternative NameDAF; CR; CROM; TC; Complement decay-accelerating factor
ReactivityHuman (Tested in Development)
IsotypeMouse IgG2a, κ
ImmunogenPurified Human Decay Accelerating Factor
ApplicationFlow cytometry (Qualified)
Concentration0.2 mg/ml
Workshop NumberV BP352, S031
Entrez Gene ID1604
RRIDAB_3690789
Storage BufferAqueous buffered solution containing ≤0.09% sodium azide.
Regulatory StatusRUO
BD 758668 RY610 Mouse Anti-Human CD55 IA10 | IRIGHT